Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

por Arendt, A.-M., Heubach, F., Maier, C. P., Giardino, S., Jung, G., Kowalewski, E., Rabsteyn, A., Amorelli, G., Seitz, C., Schlegel, P., Handgretinger, R., Lang, P.
Publicado 2023

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

por Bohl, S, von Harsdorf, S, Mulaw, M, Hofmann, S, Babiak, A, Maier, C P, Schnell, J, Hütter-Krönke, L-M, Scholl, K, Wais, V, Schlenk, R F, Bullinger, L, Ringhoffer, M, Döhner, H, Bunjes, D, Bommer, M, Kuchenbauer, F
Publicado 2016